NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $26.07 +0.12 (+0.46 %) (As of 12/6/2019 01:05 AM ET) Add Compare Today's Range$25.85Now: $26.07▼$26.4450-Day Range$19.74MA: $23.10▼$26.1152-Week Range$11.05Now: $26.07▼$26.89Volume850,254 shsAverage Volume962,476 shsMarket Capitalization$2.72 billionP/E Ratio200.54Dividend YieldN/ABeta1.04 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO Previous Symbol CUSIPN/A CIK1077183 Webhttp://www.neogenomics.com/ Phone239-768-0600Debt Debt-to-Equity Ratio0.24 Current Ratio4.24 Quick Ratio4.05Price-To-Earnings Trailing P/E Ratio200.54 Forward P/E Ratio137.21 P/E GrowthN/A Sales & Book Value Annual Sales$276.74 million Price / Sales9.84 Cash Flow$0.33 per share Price / Cash Flow79.79 Book Value$3.43 per share Price / Book7.60Profitability EPS (Most Recent Fiscal Year)$0.13 Net Income$2.64 million Net Margins0.55% Return on Equity4.60% Return on Assets3.07%Miscellaneous Employees1,500 Outstanding Shares104,408,000Market Cap$2.72 billion Next Earnings Date2/18/2020 (Estimated) OptionableOptionable Receive NEO News and Ratings via Email Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NEO Rates by TradingView NeoGenomics (NASDAQ:NEO) Frequently Asked Questions What is NeoGenomics' stock symbol? NeoGenomics trades on the NASDAQ under the ticker symbol "NEO." How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The medical research company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The company's quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share. View NeoGenomics' Earnings History. When is NeoGenomics' next earnings date? NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics. What price target have analysts set for NEO? 6 equities research analysts have issued 1 year price objectives for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' share price to reach $25.60 in the next year. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for NeoGenomics. What is the consensus analysts' recommendation for NeoGenomics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics. Has NeoGenomics been receiving favorable news coverage? News headlines about NEO stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NeoGenomics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for NeoGenomics. Are investors shorting NeoGenomics? NeoGenomics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,450,000 shares, an increase of 14.4% from the September 30th total of 5,640,000 shares. Based on an average trading volume of 770,800 shares, the days-to-cover ratio is currently 8.4 days. Approximately 6.5% of the shares of the company are short sold. View NeoGenomics' Current Options Chain. Who are some of NeoGenomics' key competitors? Some companies that are related to NeoGenomics include Neurocrine Biosciences (NBIX), West Pharmaceutical Services (WST), EXACT Sciences (EXAS), Bio-Rad Laboratories (BIO.B), Elanco Animal Health (ELAN), Henry Schein (HSIC), Bausch Health Companies (BHC), Carl Zeiss Meditec (AFX), Avantor (AVTR), Mylan (MYL), Qiagen (QGEN), Eurofins Scientific (ERFSF), Ono Pharmaceutical (OPHLF), Davita (DVA) and IPSEN S A/S (IPSEY). What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), Marvell Technology Group (MRVL), AbbVie (ABBV) and AT&T (T). Who are NeoGenomics' key executives? NeoGenomics' management team includes the folowing people: Mr. Douglas M. VanOort, Chairman & CEO (Age 64)Ms. Sharon A. Virag, Chief Financial Officer (Age 52)Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57) Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.59%), Eagle Asset Management Inc. (2.59%), Emerald Mutual Fund Advisers Trust (1.71%), Emerald Advisers LLC (1.67%), Granahan Investment Management Inc. MA (0.94%) and Russell Investments Group Ltd. (0.55%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics. Which major investors are selling NeoGenomics stock? NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Castleark Management LLC, Rice Hall James & Associates LLC, First Trust Advisors LP, Gabelli Funds LLC, Robeco Institutional Asset Management B.V. and Russell Investments Group Ltd.. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics. Which major investors are buying NeoGenomics stock? NEO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, New York State Teachers Retirement System, Squarepoint Ops LLC, Granahan Investment Management Inc. MA and State of Alaska Department of Revenue. View Insider Buying and Selling for NeoGenomics. How do I buy shares of NeoGenomics? Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is NeoGenomics' stock price today? One share of NEO stock can currently be purchased for approximately $26.07. How big of a company is NeoGenomics? NeoGenomics has a market capitalization of $2.72 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics. What is NeoGenomics' official website? The official website for NeoGenomics is http://www.neogenomics.com/. How can I contact NeoGenomics? NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected] MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 372 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 634MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: What is the S&P/ASX 200 Index?